Hsp70 modulators and methods for making and using the same

Patent metadata

Field	Value
Publication number	US-10160729-B2
Application number	US-201715842755-A
Country	US
Kind code	B2
Filing date	Dec 14, 2017
Priority date	May 13, 2014
Publication date	Dec 25, 2018
Grant date	Dec 25, 2018

Abstract

The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.

First claim

The invention claimed is:

1. A method of treating cancer in a patient in need thereof,
wherein cancer is a hematological malignancy or a solid tumor; and
wherein the method comprises administering to the patient a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
X is —N═or —CH═;
X 1 is —N═or —C(R 5 )═;
R 1 is

R 1a is

 or C 1-6 aliphatic optionally substituted with one or more groups independently selected from —OH, cyclopropyl, or 5-membered heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur;
each R 1b is independently hydrogen, C 1-4 alkyl, or two R 1b groups are optionally taken together to form an oxo group;
each of R 1c and R 1d is independently hydrogen or C 1-4 alkyl;
R 2 is —O—CH 2 -Ring A, —NH—CH 2 -Ring A, or —O—CH 2 CH 2 -Ring A;
Ring A is unsubstituted phenyl, unsubstituted furanyl,

 or pyridinyl optionally substituted with R A5 ;
each of R A1 is independently halogen, —CN, —C(O)N(R) 2 , —N(R) 2 , —OR, —C(O)R, —N 3 , an optionally substituted 5- or 6-membered heterocyclyl or heteroaryl having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur, or C 1-4 alkyl optionally substituted with one or more halogen;
each R is independently hydrogen or C 1-4 alkyl optionally substituted with one or more halogen;
R A2 is —Cl, —Br, —I, —CN, —C(O)N(R) 2 , —N(R) 2 , —OR, —C(O)R, —N 3 , C 1-4 alkyl optionally substituted with one or more halogen, or an optionally substituted 5- or 6-membered heterocyclyl or heteroaryl having one or two heteroatoms independently selected from nitrogen, oxygen or sulfur;
n is 1 to 4;
R A3 is —H or —F;
R A4 is —F or —OR;
R A5 is —OR or —N(R) 2 ;
R 3 is —C(O)N(R 3a ) 2 , —OR 3b , —C(O)H, —C(O)OR, or —N(R 3c ) 2 ;
each R 3a is independently hydrogen or C 1 alkyl optionally substituted with one or more groups independently selected from halogen or 1-pyrrolidinyl;
R 3b is hydrogen or C 1-4 alkyl optionally substituted with one or more groups independently selected from halogen, C 1-4 alkyl, C 1-4 haloalkyl, oxo, or —N(R) 2 ;
each R 3c is independently hydrogen or C 1-4 alkyl optionally substituted with one or more groups independently selected from halogen, C 1-4 alkyl, C 1-4 haloalkyl, oxo, or —N(R) 2 ;
R 4 is R, halogen, or —N(R) 2 ; and
R 5 is hydrogen, methyl or —N(R) 2 .

2. The method of claim 1 , wherein X is —N═.

3. The method of claim 1 , wherein X is —CH═.

4. The method of claim 1 , wherein R 3 is —C(O)NH 2 .

5. The method of claim 1 , wherein R 3 is —N(R 3c ) 2 .

6. The method of claim 1 , wherein R 4 is —CF 3 .

7. The method of claim 1 , wherein R 4 is halogen.

8. The method of claim 1 , wherein X 1 is —C(R 5 )═.

9. The method of claim 1 , wherein X 1 is —N═.

10. The method of claim 1 , wherein R 1 is

11. The method of claim 1 , wherein R 2 —O—CH 2 -Ring A.

12. The method of claim 1 , wherein Ring A is phenyl,

13. The method of claim 1 , wherein the compound of Formula I is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 , wherein hematological malignancy is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), Mantle cell lymphoma, B-cell lymphoma, acute lymphoblastic T cell leukemia (T-ALL), acute promyelocytic leukemia, and multiple myeloma.

15. The method of claim 14 , wherein hematological malignancy is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma (PTCL).

16. The method of claim 1 , wherein solid tumor is selected from the group consisting of colon cancer, lung cancer, bone cancer, pancreatic cancer, stomach cancer, esophageal cancer, skin cancer, brain cancer, liver cancer, ovarian cancer, cervical cancer, uterine cancer, testicular cancer, prostate cancer, bladder cancer, kidney cancer, neuroendocrine cancer, breast cancer, gastric cancer, eye cancer, gallbladder cancer, laryngeal cancer, oral cancer, penile cancer, gland

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Chiosis Gabriela
• Kang Yanlong
• Patel Hardik J
• Patel Maulik
• Ochiana Stefan
• Rodina Anna
• Taldone Tony
• Shrestha Liza

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D401/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title